Search

Your search keyword '"Zhuang Y"' showing total 42 results

Search Constraints

Start Over You searched for: Author "Zhuang Y" Remove constraint Author: "Zhuang Y" Topic carcinoma, non-small-cell lung Remove constraint Topic: carcinoma, non-small-cell lung
42 results on '"Zhuang Y"'

Search Results

1. β-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer.

2. CT-based quantification of intratumoral heterogeneity for predicting pathologic complete response to neoadjuvant immunochemotherapy in non-small cell lung cancer.

3. 13-oxyingenol dodecanoate derivatives induce mitophagy and ferroptosis through targeting TMBIM6 as potential anti-NSCLC agents.

4. Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis.

5. Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling.

6. Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.

7. New biomarker for lung cancer - focus on circSETD3.

8. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.

9. SRCIN1 Regulated by circCCDC66/miR-211 Is Upregulated and Promotes Cell Proliferation in Non-Small-Cell Lung Cancer.

10. A subset of flavaglines inhibits KRAS nanoclustering and activation.

11. SPOCK1 contributes to the third-generation EGFR tyrosine kinase inhibitors resistance in lung cancer.

12. Radiofrequency ablation of primary non-small cell lung cancer: A retrospective study on 108 patients.

13. Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional study.

14. Prognostic Factors as a Function of Disease-free Interval After Definitive (Chemo)radiation for Non-Small Cell Lung Cancer Using Conditional Survival Analysis.

15. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.

16. Survival time following resection of intracranial metastases from NSCLC-development and validation of a novel nomogram.

17. High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases.

18. Cinnamaldehyde induces apoptosis and reverses epithelial-mesenchymal transition through inhibition of Wnt/β-catenin pathway in non-small cell lung cancer.

19. Prognosis and predictors of site of first metastasis after definitive radiation therapy for non-small cell lung cancer.

20. [Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells].

21. Incidental receipt of cardiac medications and survival outcomes among patients with stage III non-small-cell lung cancer after definitive radiotherapy.

22. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes.

23. A comparison of epidermal growth factor receptor mutation testing methods in different tissue types in non-small cell lung cancer.

24. Azithromycin enhances the favorable results of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer.

25. Acute phase response before treatment predicts radiation esophagitis in non-small cell lung cancer.

26. Association between white blood cell count following radiation therapy with radiation pneumonitis in non-small cell lung cancer.

27. Do angiotensin-converting enzyme inhibitors reduce the risk of symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive radiation therapy? Analysis of a single-institution database.

28. Induction of long intergenic non-coding RNA HOTAIR in lung cancer cells by type I collagen.

29. A sequential method of epidermal growth factor receptor mutation detection reduces false negatives: a new case with doublet mutations of L833V and H835L in China.

30. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy.

31. Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer.

32. Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy.

33. Association between single nucleotide polymorphisms of the transforming growth factor β1 gene and the risk of severe radiation esophagitis in patients with lung cancer.

34. HSPB1 gene polymorphisms predict risk of mortality for US patients after radio(chemo)therapy for non-small cell lung cancer.

35. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis.

36. Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer.

37. Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer.

38. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.

39. Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer.

40. High p27 expression is associated with a better prognosis in East Asian non-small cell lung cancer patients.

41. Functional promoter rs2868371 variant of HSPB1 associates with radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with radio(chemo)therapy.

42. Predictive value of 18F-fluorodeoxyglucose uptake by positron emission tomography for non-small cell lung cancer patients treated with radical radiotherapy.

Catalog

Books, media, physical & digital resources